Home |  Contact Us | Site Map

Investor Relations

Corporate Profile

Welcome! Whether you are a potential investor in BioCryst Pharmaceuticals or you are already a shareholder, our investor center is the primary source of information about the company. Just choose a topic, or if you have a question, e-mail us.

NASDAQ: BCRX
$4.39 - 0.25
Aug 24, 2016 at 4:00 PM ET
Intraday data provided by eSignal

Recent Releases View All Releases

BioCryst Announces Initiation of the APeX-1 Clinical Trial of BCX7353 for Hereditary Angioedema
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2016 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that it has dosed the first subject in the APeX-1 cli...

Read More

BioCryst Reports Second Quarter 2016 Financial Results
RESEARCH TRIANGLE PARK, N.C., Aug. 04, 2016 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the second quarter ended June 3...

Read More

Investor Relations

Rob Bennett, Vice President Investor Relations & Operations
919.859.7910
investorrelations@biocryst.com

Proxy Online

For more information click here.

Stockholder Services

Questions about stock transfers and lost certificates should be directed to the transfer agent:
American Stock Transfer & Trust Company
59 Maiden Lane
New York, NY 10038
1-800-937-5449 (toll free in US and Canada)
1-718-921-8200 (callers outside the US and Canada)